| Bioactivity | BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes[1]. |
| CAS | 100276-03-7 |
| Formula | C20H22ClNO4 |
| Molar Mass | 375.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang L, et al. Design, Synthesis, and Biological Application of Novel Photoaffinity Probes of Dihydropyridine Derivatives, BAY R3401. Molecules. 2019 Jun 28;24(13):2394. |
BAY R3401
CAS: 100276-03-7 F: C20H22ClNO4 W: 375.85
BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibitio
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.